Novo Nordisk’s plummet is a warning for backers who’ve crowded into a relatively small group of very large stocks.

This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent ...

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription ...

Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...

Novo Nordisk selloff is an overreaction. With solid fundamentals, a strong drug pipeline & long-term upside, discover why ...

(Reuters) -Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a ...

Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...

Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...